TO ALL:
This is the news. Will we have to wait until June for further up moves?
Texas Biotech (AMEX:TXB) says Novastan shows promise
Reuters, Thursday, April 17, 1997 at 10:15
HOUSTON, April 17 (Reuter) - Texas Biotechnology Corp said
Thursday that in a a Phase III study, patients were able to
successfully undergo coronary intervention procedures while
using Novastan as the anticoagulant.
In the study, Novastan was evaluated as an alternative to
heparin in patients with a history of heparin-induced
thrombocytopenia (HIT), which is an allergic reaction to
heparin.
The study evaluated 30 patients undergoing percutaneous
transluminal coronary angioplasty (PTCA), direct atherectomy,
or stent placement.
According to Texas Biotech, significant bleeding, the most
common side effect of anti-coagulation therapy, was noted in
only one patient.
It said it anticipates using these interventional data as a
supplement to its initial NDA submission for non-interventional
patients.
Texas Biotech said it is now analyzing data from a
300-patient trial that used Novastan as anticoagulant therapy
in non-interventional patients with HIT. This is projected to
be the initial claim for Novastan.
Texas Biotech was one of the most actively traded stocks on
the American Stock Exchange Thursday morning. Shares rose 3/16
to 4-5/8. |
